Immunotherapy for osteosarcoma: Where do we go from here?

121Citations
Citations of this article
136Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Osteosarcoma is the most common bone tumor in children and young adults, with few advances in survival and treatment, especially for metastatic disease, in the last 30 years. Recently, immunotherapy has begun to show promise in various adult cancers, but the utility of this approach for osteosarcoma remains relatively unexplored. In this review, we outline the mechanisms and status of immunotherapies currently in clinical trials as well as future therapies on the horizon, and discuss their potential application for osteosarcoma.

Author supplied keywords

Cite

CITATION STYLE

APA

Wedekind, M. F., Wagner, L. M., & Cripe, T. P. (2018, September 1). Immunotherapy for osteosarcoma: Where do we go from here? Pediatric Blood and Cancer. John Wiley and Sons Inc. https://doi.org/10.1002/pbc.27227

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free